Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people, according to research published today in Cancer Research.*
Cancer Research UK-funded scientists from the University of Sheffield found that the cancer-killing action of chemotherapy can trigger a swarm of wound-healing, white blood cells to cluster around blood vessels in a treatment-hit tumour. These cells - called M2 macrophages - repair tissue damage and build new blood vessels, a process that sometimes helps the tumour to grow again after treatment.
But by treating mice with cancer with a drug** that stops these repair cells from working, the researchers markedly reduced the speed at which tumours grew back after chemotherapy.
The lead scientist on the study, Professor Claire Lewis at the University of Sheffield's Department of Oncology, said: "Scientists already knew that the body's drive to heal itself can sometimes backfire when the immune system reacts to tissue damage. Our research shows that treating tumours with chemotherapy can activate this part of the immune system, and this then helps tumours re-grow afterwards.
"But combining chemotherapy with a drug that switches off this part of the body's repair system, slowed the growth of tumours after chemotherapy. This could be particularly important for patients who can't have surgery and, therefore, need chemotherapy to help them live for as long as possible."
Clinical trials of patients are needed to confirm these early findings to see if the drug - already used in patients for other reasons, such as bone marrow transplants - could help cancer patients after chemotherapy.
Dr Áine McCarthy, science communications officer at Cancer Research UK, said: "Chemotherapy is a cornerstone cancer treatment that saves thousands of lives, but sometimes tumours come back, reducing patients' chances of survival. We don't understand all the reasons why tumours do come back, but this study sheds new light on the role of the immune system in causing tumours to grow again and, importantly, identifies a drug that could block this happening if given at the same time as chemotherapy.
"But this is early research carried out in mice and more work is needed to see if blocking M2 macrophages*** can also slow down tumour re-growth in patients."
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.
Notes to editor:
* 'Perivascular M2 macrophages stimulate tumour relapse after chemotherapy' - Russell Hughes et al. DOI: 10.1158/0008-5472.CAN-14-3587
This research was funded mainly by Cancer Research UK in Sheffield, and carried out in collaboration with Professor Jeff Pollard who is funded by the MRC and Wellcome Trust, and Dr Bin-Zhi Qian who is funded by Cancer Research UK. Both are based at the University of Edinburgh.
Researchers were based at the Departments of Oncology, University of Sheffield Medical School; MRC Centre for Reproductive Health, Queen's Medical Research Institute, University of Edinburgh; Swiss Institute for Experimental Cancer Research in Lausanne; the Memorial Sloan-Kettering Cancer Center in New York; Ottawa Hospital Research Institute and Department of Medicine, University of Ottawa; MD Anderson Cancer Center, Houston.
** Scientists used a drug called Plerixafor during this research.
*** Macrophages are a type of white blood cells and are often found in two forms in the body: M1 macrophages, which protect against infection and can work to destroy tumours, and M2 macrophages which promote wound-healing and have been linked to tumour growth and spread. Scientists in this research targeted and blocked the accumulation of M2 cells in tumours after chemotherapy.
About Cancer Research UK
- * Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
* Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
* Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
* Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
* Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
* Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
* Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.
About the University of Sheffield
With almost 26,000 of the brightest students from around 120 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world's leading universities. A member of the UK's prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines. Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in. In 2014 it was voted number one university in the UK for Student Satisfaction by Times Higher Education and in the last decade has won four Queen's Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom's intellectual, economic, cultural and social life. Sheffield has five Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields. Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
For further information, please visit http://www.
For further information please contact: Amy Pullan, Media Relations Officer, University of Sheffield, 0114 222 9859, firstname.lastname@example.org